Thyrocare, owned by PharmEasy, had a great third quarter in FY26! It’s becoming a top diagnostics brand in India’s direct-to-consumer healthcare scene. Their profit went up by 48.1% compared to last year, making ₹28.1 crore in Q3 FY26. Last year, it was ₹19 crore. This increase is because they made more money, managed things well, and kept costs down.
Sales revenue went up by 17.8% to ₹195.5 crore, from ₹165.9 crore last year. While it dipped by 9.7% from last quarter to ₹216.5 crore in Q2 FY26, the year-on-year increase shows people still want routine tests across India. They also made ₹5 crore from other sources, so their total income was ₹200.5 crore this quarter.
Thyrocare’s good at keeping costs low. They focus on prices people can pay, standard testing, and being available everywhere. Because people care more about their health, they’re getting more tests done, they like getting healthcare at home, and using online services.
Costs went up by 12.2% to ₹159.2 crore, from ₹141.9 crore in Q3 FY25. Since costs didn’t rise as fast as revenue, they made more money overall. Profit went down by 41.4% from ₹47.8 crore last quarter, mostly because of normal changes from quarter to quarter. They are still spending on operations, logistics, and technology to grow.
As part of PharmEasy, Thyrocare is key to improving India’s direct-to-consumer healthcare. They connect tests, online ordering, and sample collection. This lets them reach more people, use data to personalize things, and work well across different areas.
The testing business is holding up well in India. People need tests regularly, and the business makes good money. Thyrocare makes a profit consistently, putting it among the best direct-to-consumer healthcare brands in India.
It is expected that Thyrocare will keep growing by doing more tests, being efficient, and reaching smaller towns. Since India’s testing market and preventive healthcare are growing, the company is on track to do well in the long run.
In general, Thyrocare’s Q3 FY26 results show a business that is growing steadily. They’re balancing growth, profit, and getting things done well. This gives confidence in the future of direct-to-consumer healthcare in India.
